company background image
ALVET logo

TheraVet ENXTPA:ALVET Stock Report

Last Price

€0.99

Market Cap

€3.2m

7D

0.2%

1Y

-69.1%

Updated

26 Mar, 2024

Data

Company Financials +

TheraVet SA Competitors

Price History & Performance

Summary of all time highs, changes and price drops for TheraVet
Historical stock prices
Current Share Price€0.99
52 Week High€3.50
52 Week Low€0.82
Beta-0.27
1 Month Change-12.57%
3 Month Change-31.86%
1 Year Change-69.13%
3 Year Changen/a
5 Year Changen/a
Change since IPO-87.80%

Recent News & Updates

Recent updates

Shareholder Returns

ALVETFR BiotechsFR Market
7D0.2%-0.2%-0.4%
1Y-69.1%-1.8%10.6%

Return vs Industry: ALVET underperformed the French Biotechs industry which returned -2.2% over the past year.

Return vs Market: ALVET underperformed the French Market which returned 10.1% over the past year.

Price Volatility

Is ALVET's price volatile compared to industry and market?
ALVET volatility
ALVET Average Weekly Movement5.7%
Biotechs Industry Average Movement5.8%
Market Average Movement4.3%
10% most volatile stocks in FR Market10.0%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALVET's share price has been volatile over the past 3 months.

Volatility Over Time: ALVET's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20178Enrico Bastianellihttps://www.thera.vet/en

TheraVet SA, a veterinary biotechnology company, provides osteoarticular treatments for animals in Belgium, France, Switzerland, the United Kingdom, and the United States. The company primarily provides products for osteoarthritis, ligament and tendon injuries, and bone surgery in cats, dogs, and horses. It offers BIOCERA-VET, an injectable self-hardening phosphocalcic bone void filler for osteointegration, osteoinduction, and bone remodeling properties; and VISCO-VET, an injectable visco-regenerative gel based on hyaluronic acid, species specific plasma, and an active pharmaceutical component.

TheraVet SA Fundamentals Summary

How do TheraVet's earnings and revenue compare to its market cap?
ALVET fundamental statistics
Market cap€3.19m
Earnings (TTM)-€2.04m
Revenue (TTM)€1.30m

2.5x

P/S Ratio

-1.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALVET income statement (TTM)
Revenue€1.30m
Cost of Revenue€1.92m
Gross Profit-€621.86k
Other Expenses€1.42m
Earnings-€2.04m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 23, 2024

Earnings per share (EPS)-0.63
Gross Margin-47.87%
Net Profit Margin-156.99%
Debt/Equity Ratio15.0%

How did ALVET perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.